Listen on the go
CORRECT!
Next question
touchOPHTHALMOLOGY touchOPHTHALMOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Diabetic Retinopathy

    EU DIABETIC MACULAR RETINOPATHY PARTNER

    An Introduction to Diabetic Retinopathy

    Advances in pharmacotherapy following the introduction of anti-VEGF agents and intravitreal steroids have transformed the diabetic retinopathy treatment landscape; and new imaging techniques, such as optical coherence tomography-angiography (OCT-A), have helped to guide treatment.

    Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Diabetic Retinopathy Content

    Diabetic Macular Oedema, Diabetic Retinopathy, Macular Degeneration, Paediatric Ophthalmology, Retina/Vitreous, Posterior Segment
    Late-breaking abstracts from EURETINA 2024: Advances in retinal therapies

    The EURETINA 2024 Congress, held in Barcelona from September 19-22, brought together leading experts in ophthalmology to share the latest research and innovative treatments for retinal diseases. Among the highlights were several late-breaking abstracts that showcased promising advances in therapeutics for conditions such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and  age-related macular degeneration (AMD). These studies not only demonstrated the efficacy and safety of novel treatment options but also addressed critical unmet needs in reducing patient burden and improving long-term outcomes.

    Diabetic Retinopathy, Posterior Segment
    APX3330 for the Treatment of Diabetic Retinopathy
    Timothy W Corson

    touchREVIEWS in Ophthalmology. 2023;17(1):2–3 DOI: https://doi.org/10.17925/USOR.2023.17.1.2

    Identifying treatments that prevent diabetic retinopathy progression is a priority in current research. Patients with non-proliferative retinopathy currently have limited treatment options to prevent the progression of retinopathy and loss of vision, and therapies such as anti–vascular endothelial growth factor (VEGF) therapy, steroid injectable therapy and laser treatment are reserved for patients who advance to proliferative diabetic retinopathy or diabetic macular oedema (DMO). The […]

    Diabetic Retinopathy, Posterior Segment
    Aflibercept in Diabetic Retinopathy
    Abhinav R Bheemidi, Carolina CS Valentim, Rishi P Singh

    touchREVIEWS in Ophthalmology. 2021;15(1):18–22. DOI: https://doi.org/10.17925/OPHT.2021.15.1.23

    The National Diabetes Statistics Report 2020 estimates that of the 34.1 million adults in the USA with diabetes in 2018, 21.4% had undiagnosed disease.1 Due to an insidious disease course, diabetic complications like diabetic retinopathy (DR) are common. Among US diabetic adults, 28.5% have DR and 4.4% have vision-threatening DR.2 DR remains the leading cause of new […]

    Diabetic Retinopathy, Diabetic Macular Oedema, Posterior Segment
    Lloyd Clark, Kiaweh Eye 2021: Improvements in the Long-term Management of Diabetic Retinopathy and Diabetic Macular Oedema

    It was a pleasure to speak with Lloyd Clark (Palmetto Retina Center, West Columbia, SC, USA) about injection protocols demonstrating improvements in the long-term management of diabetic retinopathy and diabetic macular oedema, and his views on current treatment trends. Questions What injection protocols have demonstrated improvements in the long-term management of diabetic retinopathy and diabetic […]

    Diabetic Retinopathy, Posterior Segment
    Lloyd Clark, Kiaweh Eye 2021: Diabetic Retinopathy and Diabetic Macular Oedema – Trends in Transitioning Treatment

    Lloyd Clark (Palmetto Retina Center, West Columbia, SC, USA) shared with us his views on unresolved challenges in the treatment of diabetic retinopathy and diabetic macular oedema. Questions What are the unresolved challenges in the treatment of diabetic retinopathy and diabetic macular oedema? (00:22) How are dosing strategies evolving to maintain initial visual acuity gains, […]

    Diabetic Retinopathy, Posterior Segment
    Francesco Bandello, ESCRS 2020 – Anti-vascular Endothelial Growth Factor Agents and Laser for Treatment of Proliferative Diabetic Retinopathy

    It was a pleasure to catch up with our Editorial Board member, Prof. Francesco Bandello (University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy), who talked us through his recent research on anti-vascular endothelial growth factor agents combined with laser for the treatment of proliferative diabetic retinopathy. Questions Could you tell us a little about your […]

    Diabetic Retinopathy, Retina/Vitreous, Posterior Segment
    Michael Abramoff, EURETINA 2019 – AI-based diabetic retinopathy screening

    AI was a hot topic at ESRCS 2019, so we were honoured to meet with Michael Abramoff (University of Iowa) to discuss his latest research around an autonomous AI diagnostic system to assist with the diagnosis of diabetic retinopathy. Questions: 1. What are the limitations of current diagnosis of diabetic retinopathy? (0:04) 2. Could you […]

    Retina/Vitreous, Diabetic Retinopathy, Posterior Segment
    José Cunha Vaz, EURETINA 2019 – Advances in diabetic retinopathy

    Jose Cunha-Vaz (AIBILI, Coimbra, Portugal) discusses the most important updates on diabetic retinopathy from EURETINA 2019, and shares advice with early career ophthalmologists on having a successful career. Questions: 1. What recent advances in diabetic retinopathy have had the biggest impact on your practice? 0:04 2. What are the most important updates in the area […]

    Diabetic Retinopathy, Posterior Segment
    Thomas Fenech, SOE 2019 – Updates in diabetic retinopathy

    Thomas Fenech (Mater Dei Hospital, Msida, Malta) shares his thoughts on the most recent developments in diabetic retinopathy and the most promising areas of research for the future. Questions: 1. What have been the most significant recent developments in diabetic retinopathy? (0:04) 2. Discuss the current unmet needs and/or the challenges you face when treating […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchOPHTHALMOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup